4.8 Article

Caloric restriction mimetics: towards a molecular definition

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 13, Issue 10, Pages 727-740

Publisher

NATURE PORTFOLIO
DOI: 10.1038/nrd4391

Keywords

-

Funding

  1. Ligue contra le Cancer (equipe labellisee)
  2. Agence National de la Recherche
  3. Association pour la Recherche sur le Cancer
  4. Canceropole Ile-de-France
  5. Institut National du Cancer (INCa)
  6. Fondation Bettencourt-Schueller
  7. Fondation de France
  8. Fondation pour la Recherche Medicale
  9. European Commission (ArtForce)
  10. European Research Council
  11. LabEx Immuno-Oncology
  12. SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate)
  13. Cancer Research and Personalized Medicine (Carpem)
  14. Paris Alliance of Cancer Research Institutes
  15. APART (Austrian Programme for Advanced Research and Technology) fellowship of the Austrian Academy of Sciences at the Institute of Molecular Biosciences, University of Graz, Austria
  16. Austrian Science Fund FWF [LIPOTOX, I1000, P23490-B12, P24381-B20]
  17. Austrian Science Fund (FWF) [P 24381, P 23490] Funding Source: researchfish
  18. Austrian Science Fund (FWF) [P23490, P24381, I1000] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

Caloric restriction, be it constant or intermittent, is reputed to have health-promoting and lifespan-extending effects. Caloric restriction mimetics (CRMs) are compounds that mimic the biochemical and functional effects of caloric restriction. In this Opinion article, we propose a unifying definition of CRMs as compounds that stimulate autophagy by favouring the deacetylation of cellular proteins. This deacetylation process can be achieved by three classes of compounds that deplete acetyl coenzyme A (AcCoA; the sole donor of acetyl groups), that inhibit acetyl transferases (a group of enzymes that acetylate lysine residues in an array of proteins) or that stimulate the activity of deacetylases and hence reverse the action of acetyl transferases. A unifying definition of CRMs will be important for the continued development of this class of therapeutic agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available